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Abstract
Background/Aims: We identified carnosinase-1 (CN-
1) as risk-factor for diabetic nephropathy (DN). Car-
nosine, the substrate for CN-1, supposedly is a pro-
tective factor regarding diabetic complications. In this
study, we hypothesized that carnosine administration
to diabetic rats might protect the kidneys from
glomerular apoptosis and podocyte loss. Methods:
We examined the effect of oral L-carnosine adminis-
tration (1g/kg BW per day) on apoptosis, podocyte
loss, oxidative stress, AGEs and hexosamine path-
way in kidneys of streptozotocin-induced diabetic
Wistar rats after 3 months of diabetes and treatment.
Results: Hyperglycemia significantly reduced endog-
enous kidney carnosine levels. In parallel, podocyte
numbers significantly decreased (-21% compared to
non-diabetics, p<0.05), apoptotic glomerular cells
numbers increased (32%, compared to non-diabetic,
p<0.05) and protein levels of bax and cytochrome c
increased (175% and 117%). Carnosine treatment
restored carnosine kidney levels, prevented podocytes
loss (+23% compared to diabetic, p<0.05), restrained
glomerular apoptosis (-34% compared to diabetic;
p<0.05) and reduced expression of bax and cyto-
chrome c (-63% and -54% compared to diabetics,
both p<0.05). In kidneys of all diabetic animals, lev-
els of ROS, AGEs and GlcNAc-modified proteins were
increased. Conclusion: By inhibition of pro-apoptotic
signaling and independent of biochemical abnormali-
ties, carnosine protects diabetic rat kidneys from
apoptosis and podocyte loss.
Introduction
Diabetic kidney disease (DKD) is a frequent com-
plication of both diabetes mellitus type 1, and type 2. About
one third of patients with DKD will progress to overt
diabetic nephropathy (DN) within 5-15 years. ROS pro-
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duction, non-enzymatic glycosylation and an increased
flux through the hexosamine pathway are important bio-
chemical changes in hyperglycaemic patients and that
are causally linked to the development of DN [1-3]. Early
in the development of DN, these biochemical changes
cause apoptosis of different glomerular cells [4-6], thereby
promoting the development of DN [7, 8]. Apoptosis of
glomerular cells is supposed to be causally related to DN,
as development of DN can completely be prevented by
inhibiting apoptosis in the glomerulus [9].
At the onset of DN, podocytes are key targets for
glomerular injury [10-13]. Podocytes loss occurs either
by apoptosis or by detachment from the glomerular base-
ment membrane [5]. Hence, numbers of podocytes per
glomerulus gradually decline in the course of DN [11]
and this change is highly predictive of both progressive
glomerular injury and long-term albumin excretion in dia-
betic patients [14]. Thus, podocyte apoptosis seems to
precede the development of DN and determines at least
in part kidney function in diabetic patients.
In contrast to other diabetic complications, only
20-40% of diabetic patients are susceptible to develop
DN which seems to be genetically determined [15, 16].
We recently identified a polymorphism in the signal
sequence of the CNDP1 gene, encoding the serum
carnosinase (CN-1), to be associated with susceptibility
to DN. Since DN occurs significantly less frequent
in diabetic patients that are homozygous for the
shortest allelic form, i.e. (CTG)5 (the so-called CNDP1
Mannheim allele), the Mannheim-allele appears to be
protective in terms of susceptibility to DN [17]. This can
be explained by the fact that the (CTG)5 allele
corresponds with a low CN-1 secretion efficiency [18]
and hence with a low serum CN-1 enzyme activity [17,
19]. Because carnosine, the natural substrate for CN-1,
has potential intrinsic renal protective properties [20-24]
a low CN-1 expression or activity is beneficial for diabetic
patients. Carnosine may prevent apoptosis [25-27] and
up-regulates defensive mechanisms such as heat shock
proteins [28].
Short-term carnosine administration has been shown
to protect against ischemia-reperfusion damage [29-33],
and chronic oral carnosine administration can retard onset
of diabetes in db/db mice [34]. However, whether
carnosine can protect against DN has not been
investigated yet. In the present study we therefore tested
the effect of oral carnosine administration on early diabetic
changes in STZ-induced diabetic rat kidneys, i.e.
biochemical abnormalities, glomerular cell apoptosis and
podocyte loss.
Materials and Methods
Animals and Diabetes Induction
The study was performed in accordance with the ARVO
statement for the use of animals in ophthalmic and vision re-
search and all animal procedures were approved by the
Regierungspräsidium Karlsruhe. Male Wistar rats (Harlan Labo-
ratories, Inc.) were housed in a 12h light/dark cycle with free
access to food and drinking water. Animals were randomly di-
vided into three groups: 24 non-diabetic rats, 46 diabetic rats
and 32 diabetic rats substituted with carnosine. Rats of the
diabetic groups were rendered diabetic by intravenous injec-
tion of streptozotocin (45mg/kg, Roche, Mannheim, Germany)
diluted in citrate buffer (pH 4.5). Animals were considered dia-
betic when blood glucose reached stable levels over 250 mg/
dl. Insulin was occasionally given to individual diabetic rats to
prevent critical weight loss. Metabolic data (body weight and
blood glucose) were measured every week and blood samples
for the determination of glycated haemoglobin concentration
by affinity chromatography (MicromatII™; Bio-Rad Laborato-
ries GmbH, Munich, Germany) were collected at the end of the
study (n= 7-9 per group). All rats were sacrificed after 3 month
of diabetes. Kidneys were taken out immediately and washed
carefully in ice cold PBS. For histology and immunohistochem-
istry, kidneys were subsequently fixed in 4% formalin. For west-
ern blot analysis, kidney cortex was isolated, washed thor-
oughly and frozen at -80°C until further processing.
Carnosine Supplementation
Diabetic Wistar rats were divided into two groups one
week after diabetes induction. One diabetic control group, re-
ceiving pure water and a second diabetic group receiving wa-
ter supplemented with 1 g of carnosine/kg body weight (Flamma
S.p.a., Chignolo d’Isola, Italy). Carnosine was dissolved in the
daily drinking volume. Water consumption and body weights
of each cage were assessed once a week. L-carnosine–supple-
mented drinking water and lightproof bottles were replaced
every day. Carnosine concentration in kidney tissue was meas-
ured fluorometically by high-performance liquid chromatogra-
phy as previously described by Janssen et al. [17] and Schonherr
[35].
Renal histology
2 micrometer kidney paraffin sections were stained with
periodic acid–Schiff (PAS) and hematoxylin according to stand-
ard staining protocols. An investigator evaluated kidney his-
topathology in a blinded fashion and graded the glomerular
damage including mesangial matrix expansion, hyalinosis with
focal adhesion, capillary dilation, glomerular tuft occlusion and
sclerosis.
Detection of glomerular cell apoptosis
DNA strand breaks in apoptotic cells were visualized in 4
micrometer kidney paraffin sections using terminal transferase
dUTP nick-end labelling (TUNEL, In Situ Cell Death Detection
Kit, POD; Roche, Mannheim, Germany) according to the manu-
facturer’s instructions. In brief, sections were deparaffinised
and treated with 2% H2O2 /Methanol to block endogenous
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peroxidase. Thereafter, slides were incubated with the TUNEL
reaction mixture containing TdT and fluorescein d-UTP. After
incubation, incorporated fluorescein was detected with an anti-
fluorescein antibody conjugated with POD. Finally, the
immuncomplexed POD was visualized by a substrate reaction
using the DAB Peroxidase substrate kit (Vector Laboratories/
LINARIS Biologische Produkte GmbH, Wertheim, Germany),
followed by nuclear counterstaining. TUNEL positive nuclei
were counted in 10 randomly selected kidney glomeruli per
animal by two independent persons and their numbers were
expressed relative to the corresponding glomerular area as as-
sessed by an image analyzing system (CUE-2; Olympus
Opticals, Hamburg, Germany).
Quantification of podocyte loss
Paraffin-embedded, formalin-fixed, 3-µm-thick kidney sec-
tions were deparaffinised, treated with 2% H2O2 /methanol to
block endogenous peroxidase, and microwaved at 500 W and
270 W for 10 min each in citrate buffer. The sections were then
incubated with a polyclonal antibody to Wilms’ tumor 1 protein
(Santa Cruz biotechnology Inc., Heidelberg, Germany) for 1 h
at room temperature. After incubation with an appropriate POD
coupled secondary antibody, POD was visualized by a substrate
reaction using the DAB Peroxidase substrate kit (Vector Labo-
ratories/ LINARIS Biologische Produkte GmbH, Wertheim,
Germany), followed by nuclear counterstaining.
Podocytes were identified according to cell shape, locali-
zation and positivity to wt-1 staining. Total numbers of
podocytes were counted in kidney sections of randomly se-
lected animals by two independent persons in 10 randomly
selected kidney glomeruli per animal. The data are expressed
as podocyte numbers relative to the corresponding glomerular
area as assessed by an image analyzing system (CUE-2; Olym-
pus Opticals, Hamburg, Germany).
Western Blot
In order to isolate proteins from kidney cortex, frozen
tissue was homogenized mechanically on ice. Proteins were
extracted from lysates using a lysis buffer containing 125 mM
NaCl, 10 mM EDTA, 25 mM Hepes, 10 mM Na3VO4, 0.5 % de-
oxycholic acid, 0.1 % SDS, 1% Triton-X-100, phosphatase-In-
hibitor (Sigma, Steinheim, Germany) and Protease-Inhibitor
(Roche, Mannheim, Germany). Insoluble debris was removed
by centrifugation at 14.000g at 4°C for 10 minutes. Protein ex-
tracts were heated in Laemmli-sample buffer (Bio-Rad Labora-
tories GmbH, Munich, Germany) for 5 min at 100°C prior to
separation by SDS-PAGE. Thereafter, proteins were
electrophoretically transferred to a PDVF membrane. Depend-
ing on the primary antibody applied, membranes were blocked
with either 5 % skimmed milk or 5 % BSA in TBS according to
the manufacturer’s recommendations. For detection of
apoptosis signalling, antibodies against cytochrome c and Bax
(Cell Signalling Technology, Danvers, USA) were utilized. Bio-
chemical changes in the kidney were detected by antibodies
directed against carboxymethyl-lysine- (CML, [36]),
nitrotyrosine- (Alexis Biochemicals, Axxora Deutschland
GmbH, Germany), methylglyoxal (methylglyoxal-H1, [37]) and
N-Acetylglucosamine-modified proteins (Abcam plc, Cam-
bridge, United Kingdom). All antibodies were diluted and incu-
bated as recommended by the manufacture. Immunoblots were
made visible on Amersham Hyperfilms (Amersham, Bucking-
hamshire UK) by incubating the membranes with appropriate
HRP-coupled secondary antibodies (Santa Cruz Biotechnol-
ogy, Heidelberg, Germany) and by using enhanced chemilumi-
nescence (PerkinElmer, LAS, USA). For loading control, mem-
branes were stripped and re-probed with antibodies directed
against GAPDH (GAPDH antibody - Loading Control, Abcam
plc, Cambridge, United Kingdom). Intensity of the bands was
measured by densitometry using the ImageJ 1.36b software.
Statistical analysis
All data are expressed as mean ± SD. Data analysis was
performed by using unpaired two-tailed student T-test and a P
value less than 0.05 was considered as statistically significant.
Results
All diabetic rats developed stable hyperglycemia of
more than >250 mg/dl two weeks after diabetes induc-
tion. Average blood glucose levels were significantly el-
evated in the diabetic rats (Fig. 1B; measurement at 3
month: non-diabetic vs. diabetic: 123 ± 36 mg/dl and 585
± 26 mg/dl; p<0.05 and non-diabetic vs. diabetic with
carnosine: 123 ± 36 mg/dl and 592 ± 14 mg/dl; p<0.05;
diabetic vs. diabetic with carnosine not significant). The
increase in body weight was significantly impaired after
the onset of hyperglycemia resulting in reduced body
weights at the end of the study (non-diabetic vs. diabetic:
457 ± 35 g and 282 ± 25 g; p<0.05 and non-diabetic vs.
diabetic with carnosine: 457 ± 35 g and 292 ± 38 g; p<0.05;
diabetic vs. diabetic with carnosine not significant; Fig.
1A). Glycated haemoglobin levels were 2.3 fold increased
in diabetic rats and 1.9 fold in diabetic rats supplemented
with carnosine (non-diabetic vs. diabetic: 5.9 ± 0.4 %
and 13.4 ± 3.4 %; p<0.05 and non-diabetic vs. diabetic
with carnosine: 5.9 ± 0.4 % and 11.2 ± 2.8; p<0.05; dia-
betic vs. diabetic with carnosine not significant; Fig. 1C).
As depicted in Fig. 1D, carnosine levels were significantly
decreased in diabetic kidneys (-98% compared to non-
diabetic; non-diabetic vs. diabetic: 150.0 µg/g ± 3.5 and
3.3 µg/g ± 0.7; p<0.05) two weeks after diabetes induc-
tion. In diabetic rats that were fed with carnosine, renal
carnosine concentrations increased significantly (diabetic
vs. diabetic with carnosine: 3.3 µg/g ± 0.7 and 300.0 µg/
g ± 102.8; p<0.05) and were higher than in non-diabetic
rats (+89% compared to non-diabetic; non-diabetic vs.
diabetic with carnosine, p not significant). Kidney his-
topathology was examined in PAS and hematoxylin
stained kidney sections. Mild glomerulosclerotic changes,
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indicating an early and not advanced stage of a diabetic
kidney damage, were found in the diabetic animals. No
significant difference was found between the treated and
the non treated group (Fig. 2).
To evaluate the effect of carnosine treatment on
glomerular apoptosis, DNA strand breaks were assessed
by in situ TUNEL staining. Three months after the onset
of diabetes the numbers of TUNEL positive cells were
significantly increased in non-treated diabetic rats (+32%
compared to non-diabetics, non-diabetics: 0.0014 ± 0.0007
TUNEL+ cells/glomerular area and diabetics: 0.0019 ±
0.00018 TUNEL+ cells/glomerular area, p<0.05, Fig. 3A,
B). In carnosine treated diabetic animals, the numbers of
TUNEL positive cells were reduced by -40% compared
to diabetic animals (diabetics: 0.0019 ± 0.000018
TUNEL+ cells/glomerular area and diabetics with car-
nosine: 0.0013 ± 0.00007 TUNEL+ cells/glomerular area,
p<0.05 compared to diabetics, diabetics with carnosine
vs. non-diabetics not significant, Fig. 3A, B).
We further investigated the anti-apoptotic potential
of carnosine by western blot analysis of kidney cortex
lysates. Immunoblots stained for pro-apoptotic bax and
cytochrome c displayed an increased expression of
+175%, and +117% respectively in the diabetic kidneys
of non-treated rats (p<0.05 for both, Fig. 3C-F). Carnos-
ine treatment significantly inhibited hyperglycemia-in-
duced upregulation of bax (-63% compared to diabetics,
p<0.05) and cytochrome c (-54% compared to diabetics,
p<0.05) in diabetic kidneys (Fig. 3C-F).
To investigate whether carnosine treatment can pre-
vent podocyte loss in diabetic rats, we determined
glomerular podocyte numbers using wt-1 as podocyte
marker in histological kidney sections. Podocytes num-
bers were significantly reduced in diabetic kidneys (-21%
compared to non-diabetics, non-diabetics: 0.0018 ±
0.00023 WT-1+ cells/glomerular area and diabetics:
0.0014 ± 0.00018 WT-1+ cells/glomerular area, p<0.05,
Fig. 4A, B), while in diabetic rats fed with carnosine,
podocyte numbers were normalized (+23% compared to
diabetics, diabetics: 0.0014 ± 0.00018 WT-1+ cells/
Fig. 1. The influence of oral carnosine treatment on STZ-in-
duced hyperglycaemia and renal carnosine levels. Body weights
(Panel A) and blood glucose levels (Panel B) of non-diabetic
(NC, z), diabetic (DC, ) and diabetic rats treated with carno-
sine (DC+C, S) were monitored over 12 weeks. In comparison
to non-diabetic controls, all diabetic animals developed stable
hyperglycemia and showed reduced body weights. Moreover,
after 3 months levels of HbA1c were elevated in the diabetic
animals. This was independent of carnosine treatment *=p<0.05
vs NC (Panel C). Measurement of renal carnosine by HPLC
(Panel D) revealed that endogenous carnosine levels are re-
duced in diabetic animals and oral carnosine treatment increased
renal carnosine levels above that of non diabetic controls
*=p<0.05 vs NC, #=p<0.05 vs NC.
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glomerular area and diabetic with carnosine: 0.0017 ±
0.00022 WT-1+ cells/glomerular area, p<0.05 and -4%
compared to non-diabetics, p not significant, Fig. 4A, B).
To examine the influence of carnosine on the bio-
chemical abnormalities induced by diabetes, the activity
of three cells damaging mechanisms investigated by west-
ern blotting. To this end, antibodies directed against
nitrosylated (NT, Fig. 5A) and carboxymethyl-lysine
(CML, Fig. 5C) -modified proteins as markers of oxidative
stress were used. Moreover, immunoblots were incubated
Fig. 2. Kidney histopathology. Kidney sec-
tions were stained with PAS and hematoxylin
to evaluate the grade of the glomerular dam-
age. The figure shows representative pic-
tures of kidney section from non-diabetic
(NC), diabetic (DC), and diabetic rats treated
with carnosine (DC+C). In DC and DC+C a
slight increase of mesangial matrix and/or
hyalinosis was evident. Conformable with
an early stage of diabetic kidney damage, no
further signs of glomerulosclerosis were
found in DC and DC+C.
Fig. 3. The influence of carnosine treatment
on hyperglycemia-induced glomerular
apoptosis. Apoptosis was tested by TUNEL
staining and by western blot analysis using
kidneys of non-diabetic (NC), diabetic (DC),
and diabetic rats treated with carnosine
(DC+C) Panel A: Representative pictures of
kidney sections stained by TUNEL. Arrows
indicate cells counted as TUNEL positive.
Original magnification 400x. Panel B: Quan-
tification of TUNEL positive cells was per-
formed in a blinded fashion on ten randomly
selected glomeruli per animal (n=4, for each
group) by two independent investigators.
Results are expressed as mean TUNEL posi-
tive cells/glomerular area ± SD. Note that
there is no significant difference (n.s.) in the
proportion of TUNEL positive cells in NC
vs. DC+C, but a significant increase in DC.
*=p<0.05 compared to non-diabetic controls
and #=p<0.05 compared to diabetics. Panel
C, E: Representative immunoblots stained
with antibodies directed against bax and cy-
tochrome c, respectively. Antibodies di-
rected against GAPDH were used to control
for equal loading. Panel D, F: Quantification
of bax and cytochrome c protein expression
by densitometry measurement of immunore-
active bands. A total of 5-6 animals per group
were evaluated. Ratios of bax/GAPDH or cy-
tochrome c/GAPDH were calculated to avoid
loading dissimilarity errors. Results are ex-
pressed as mean ration ± SD relative to NC.
*=p<0.05 compared to non-diabetic controls
and #=p<0.05 compared to diabetics.
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Fig. 4. The influence of carnosine treat-
ment on diabetic podocyte loss.
Podocytes were stained with antibodies
directed against wt-1 in kidney sections
of non-diabetic (NC), diabetic (DC), and
carnosine treated diabetic (DC+C) rats
Panel A: Representative pictures of kid-
ney sections stained for wt-1. Arrows
indicate wt-1 positive cells. Original mag-
nification 400x. Panel B: Quantification
of wt-1 positive cells was performed in a
blinded fashion on ten randomly selected
glomeruli per animal (n=4, for each group)
by two independent investigators. Re-
sults are expressed as mean podocyte
numbers relative to the corresponding
glomerular area ± SD. No significant dif-
ference (n.s.) in podocyte numbers were
found between NC and DC+C, whereas
podocyte numbers were significantly re-
duced in DC. *=p<0.05 compared to non-
diabetic controls and #=p<0.05 compared
to diabetics.
with antibodies directed against methylglyoxal- (MG, Fig.
5E) and GlcNAc-modified proteins (Fig. 5G) in order to
assess AGE-production and the activity of the hexosamine
pathway. In diabetic kidney cortex, the levels of NT- (Fig.
5B) and of CML- (Fig. 5D) modified proteins were sig-
nificantly increased (+ 167% and +88%, respectively,
p<0.05 for both compared to non-diabetics). Likewise,
the levels of MG- and GlcNAc-modified proteins were
increased in diabetic kidney lysates (+250% and +326%,
respectively compared to non-diabetics, p<0.05, Fig. 5F
and H). Carnosine treatment of diabetic rats had no ef-
fect on hyperglycemia-induced increase in NT-, CML-,
MG- and N-Acetylglucosamine-protein levels (diabetic
with carnosine vs. non-diabetics: +204% for NT, +122%
for CML, +333% for MG and +230%, all p<0.05 com-
pared to non-diabetics, diabetics with carnosine vs. dia-
betics not significant).
Discussion
Experimental evidence suggests that the carnosine-
carnosinase system might play an important role in dia-
betes associated complications, in particular in DN [17,
34]. Diabetic patients that are homozygous for the
Mannheim allele (CTG)5 are less affected by DN. This
genotype is associated with a low serum CN-1 activity,
most likely because the (CTG)5 repeat in the signal pep-
tide of CN-1 influences CN-1 secretion [18]. Inasmuch
as individuals homozygous for the Mannheim allele de-
velop less frequently DN, it is conceivable that the pro-
tective effect of the Mannheim allele is directly related
to the amount of CN-1 found in serum.
A number of studies conducted in recent years have
suggested that carnosine, the substrate of CN-1, might
be beneficial in relation to diabetic complications diabe-
tes [17, 24, 34, 38]. Hence, a low carnosine turnover in
(CTG)5 homozygous patients could be a plausible expla-
nation why these patients develop less frequently DN.
Yet, definitive proof for the salutary effect of carnosine
in terms of preventing hyperglycaemia mediated damage
in renal tissue is still lacking. In the present study, we
therefore investigated whether oral carnosine treatment
can ameliorate early changes in kidneys of streptozotocin-
induced diabetic rats. The main findings of this study are
the following. Carnosine treatment prevents the up-regu-
lation of pro-apoptotic molecules in the kidneys of dia-
betic rats. It also prevented podocyte loss in these rats.
This is independent of major biochemical abnormalities
that occur as a consequence of diabetes, since carnosine
did not influence NT, CML, methylglyoxal or GlcNAc
expression in kidneys of diabetic rats.
Microvascular complications in diabetic patients are
for a great deal causally related to an increased produc-
tion of ROS, AGEs and GlcNAc-modified proteins,
evoked by chronic hyperglycemia. Based on the intrinsic
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Fig. 5. The effect of carnosine treatment on oxidative stress, AGE formation and activity of the hexosamine pathway in diabetic
kidney cortex. In order to assess the effect of carnosine treatment on hyperglycemia-induced biochemical changes, kidney cortex
lysates from non-diabetic (NC), diabetic (DC), and diabetic rats treated with carnosine (DC+C) were probed with antibodies
against nitrotyrosine- (NT, Fig. 4A, B) and carboxymethyl-lysine- (CML, Fig. 4C, D) modified proteins as markers of oxidative
stress, methylglyoxal- (MG, Fig. 4E, F) modified proteins as a marker for AGE-production and N-acetyl-D-glucosamine- (GlcNAc,
Fig. 4G, H) modified proteins as a marker for hexosamine pathway activation. Representative immunoblots (Fig. 4A, C, E, G) and
corresponding densitometrical quantifications (Fig. 4B, D, F, H) show a significant increase of all the markers in diabetic kidneys,
irrespective of carnosine treatment. Ratios between the different biochemical markers and GAPDH were assessed to avoid
loading dissimilarity errors. A total of 3 animals per group were evaluated for each marker. Results are expressed as mean ratio ±
SD. *=p<0.05 compared to non-diabetic.
biochemical properties of carnosine, i.e. antioxidant ef-
fects and inhibition of AGE formation [22, 24, 39-42],
we expected that carnosine feeding would counteract
these factors in kidneys of diabetic rats. Yet surprisingly,
our results clearly show that carnosine feeding of
diabetic rats is neither capable of preventing oxidative
stress and AGE formation, nor could carnosine prevent
the activation of the hexosamine pathway in our
experimental setting, despite of carnosine feeding
significantly increased renal carnosine concentrations.
However, it is wise to take some caution in stating that
carnosine has antioxidant activity, as most of the data
that support this assumption are derived from in vitro
cell culture studies [43, 44]. Similar to our findings,
Aruoma et al [43] have questioned the anti-oxidative
property of carnosine in vivo and they concluded from
their study that it is possible that carnosine could act as
physiological antioxidant by scavenging hydroxyl radicals,
but it does not have a broad spectrum of antioxidant ac-
tivity, and its ability to inhibit lipid peroxidation is not well
established.
Similarly, the ability of carnosine to inhibit AGE
formation was mostly demonstrated in in vitro experi-
ments. Nonetheless, it has been repeatedly shown that
carnosine is protective in models of ischemia reperfusion
[29-33]. In terms of oxidative challenge, these models
clearly differ from the diabetic model where sustained
severe hyperglycemia over a period of 3 months may
yield a higher oxidative burden compared to a relative
short period of ischemia. It might well be that the protec-
tive biochemical characteristics of carnosine to counter-
act oxidative stress and hyperglycemia-induced protein
modification in the diabetic kidney are exhausted by se-
verity and duration of experimental diabetes. Besides, it
has to be admitted that the antioxidant and AGE inhibit-
ing capacity of carnosine can still be sufficient to protect
the glomerular capillaries the surrounding parenchymal
cells. Such a localized effect would be bound to go unno-
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ticed in western blot analysis.
Nonetheless, this study does show that carnosine
has a cell protective effect in the context of diabetes, as
apoptosis of glomerular cells and podocyte loss were sig-
nificantly diminished by carnosine. Since carnosine is a
multifunctional dipeptide involved in numerous physiologi-
cal processes, e.g. pH buffering [45, 46], enzyme regula-
tion [47], and induction of heat shock proteins [28], these
properties may equally contribute to the cytoprotective
effect of carnosine.
Hyperglycaemia causes mitochondrial stress, an eli-
gible condition for the induction of apoptosis. Apoptosis
is believed to play an important role in a number of
glomerular diseases including DN [48], and is most likely
caused by changing the balance in the expression of the
anti- and pro-apoptotic molecules Bcl-2 and Bax respec-
tively. While Bcl-2 expression may account for maintain-
ing glomerular hypercellularity, Bax expression might be
more important in cell loss leading to glomerulosclerosis.
Bax forms oligomers thereby increasing mitochondrial
permeability and facilitating the release of cytochrome c
from the mitochondrial intermembrane space. Once re-
leased from the mitochondria, cytochrome c further acti-
vates apoptosis. In our model both bax as well as cyto-
chrome c expression were increased in the cortex of dia-
betic rats, pointing out that pro-apoptotic signalling is ac-
tive in the diabetic kidneys. In line with this observation,
quantification of TUNEL stained kidney sections revealed
increased glomerular apoptosis in diabetic rats. This
shift towards apoptosis was restrained by carnosine
treatment, indicating a cytoprotective effect of carnosine
on glomerular cells. Recently, Isermann et al. demon-
strated that DN can be prevented by protecting
glomerular endothelial cells and podocytes against
apoptosis [9]. Interestingly, carnosine showed similar ef-
fects as reported for activated protein C in the study of
Iserman et al., in that both molecules down-regulated bax
and cytochrome c and reduced TUNEL positive cells in
diabetic animals.
The increase in glomerular apoptosis, and in parallel
podocyte loss, in diabetic kidneys was significantly amel-
iorated by carnosine treatment. Although this study did
not address the exact identity of the glomerular apoptotic
cells, it is likely that part of these cells were of podocyte
origin, as podocyte loss and glomerular cell apoptosis
coincided. In human disease and in experimental models
podocyte loss has been linked to the development of pro-
teinuria and glomerulosclerosis [49] and is predictive for
the progression of DN [14, 50-52]. In keeping with the
central role of podocytes in the glomerular architecture
and the beneficial effect of carnosine treatment on
podocyte loss, our results may indicate that carnosine could
protect from DN. Moreover, the clear pro- and anti-
apoptotic effect that we have observed in western blot
analysis might not represent changes limited to the
glomerulus and cells situated in areas outside of the
glomerulus might also be protected by carnosine. There-
fore, carnosine could have a broader therapeutic spec-
trum that goes beyond the salutary effect demonstrated
in this study.
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